Jesse2233
Senior Member
- Messages
- 1,942
- Location
- Southern California
@Jonathan Edwards
Hi Professor, would you say that the reason for fewer successful outcomes in off-trial Rituximab treatments vs Fluge / Mella's trials is...
1. An incorrect maintenance portocol?
2. Specific patient selection criteria in the Norway trials (or a regionally definedl etiology)?
3. An incorrect inital dosage rate/size?
4. Lack of a controlled setting?
5. A combination of the above?
6. Another reason?
Or is the premise of my question flawed in that we don't have a significant sample of off-trial treatments from which to draw a comparison?
Anyone else feel free to jump in!
Thank you!
Hi Professor, would you say that the reason for fewer successful outcomes in off-trial Rituximab treatments vs Fluge / Mella's trials is...
1. An incorrect maintenance portocol?
2. Specific patient selection criteria in the Norway trials (or a regionally definedl etiology)?
3. An incorrect inital dosage rate/size?
4. Lack of a controlled setting?
5. A combination of the above?
6. Another reason?
Or is the premise of my question flawed in that we don't have a significant sample of off-trial treatments from which to draw a comparison?
Anyone else feel free to jump in!
Thank you!